SCHEMBL5720902

SCHEMBL5720902

CCCOC(=O)CC(N)c1ccncc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 2/20 0.42
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 1/20 0.40
ALOX15 P16050 1/20 0.40
LMNA P02545 5/20 0.37
NPC1 O15118 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
STAT3 P40763 1/20 0.36
ROCK1 Q13464 2/20 0.36
ROCK2 O75116 1/20 0.36
DYRK3 O43781 1/20 0.36
PRKACA P17612 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2887929 0.88 ALDH1A1 (0.43) CYP19A1ALDH1A1KDM4ELMNAKMT2A
SCHEMBL1138690 0.84 LMNA (0.49) ALDH1A1LMNACYP2D6CYP1A2SMN1; SMN2
SCHEMBL27682265 0.84 LMNA (0.49) ALDH1A1LMNACYP2D6CYP1A2SMN1; SMN2
SCHEMBL5720971 0.84 LMNA (0.49) ALDH1A1LMNACYP2D6CYP1A2SMN1; SMN2
SCHEMBL5720907 0.83 ESR1 (0.50) ALDH1A1KDM4EALOX15LMNACYP3A4
SCHEMBL5720901 0.83 ALDH1A1 (0.40) ALDH1A1KDM4ELMNASMN1; SMN2MEN1
SCHEMBL5720960 0.83 NPC1 (0.44) LMNANPC1CYP1A2CYP2C9CYP2C19
SCHEMBL5720794 0.82 ALDH1A1 (0.40) ALDH1A1KDM4ELMNACYP2C9CYP2C19
SCHEMBL5720928 0.82 CYP2C9 (0.41) ALDH1A1LMNACYP3A4CYP2D6CYP1A2
SCHEMBL5720856 0.82 MEN1 (0.40) ALDH1A1KDM4ELMNACYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060178433-A1 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto UBE INDUSTRIES, LTD. (JP) 2006-08-10 US disclosed
EP-1621529-A1 3-AMINO-3-ARYLPROPIONIC ACID n-ALKYL ESTERS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-AMINO-3-ARYLPROPIONIC ACIDS AND ESTERS OF THE ANTIPODES THERETO Ube Industries, Ltd. (JP) 2006-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178433-A1 3-Amino-3-arylpropionic acid n-alkyl esters, process for production thereof, and process for production of optically active 3-amino-3-arylpropionic acids and esters of the antipodes thereto ALAD, ARSA, ALDH7A1 CYP19A1 166/4885ALDH1A1 258/4885KDM4E 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.